175 related articles for article (PubMed ID: 32741365)
1. Can clinical and urodynamic parameters predict the occurrence of neutralizing antibodies in therapy failure of intradetrusor onabotulinumtoxin A injections in patients with spinal cord injury?
Tiburtius C; Böthig R; Kowald B; Hirschfeld S; Thietje R
BMC Urol; 2020 Aug; 20(1):113. PubMed ID: 32741365
[TBL] [Abstract][Full Text] [Related]
2. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
[TBL] [Abstract][Full Text] [Related]
3. Video-Urodynamic Characteristics and Predictors of Switching from Botulinum Neurotoxin a Injection to Augmentation Enterocystoplasty in Spinal Cord Injury Patients.
Lin CC; Kuo HC
Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051024
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.
Chen CY; Liao CH; Kuo HC
Spinal Cord; 2011 May; 49(5):659-64. PubMed ID: 21243000
[TBL] [Abstract][Full Text] [Related]
5. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.
Linsenmeyer TA
J Spinal Cord Med; 2013 Sep; 36(5):402-19. PubMed ID: 23941788
[TBL] [Abstract][Full Text] [Related]
6. Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder.
Chen SF; Chang CH; Kuo HC
Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27249005
[TBL] [Abstract][Full Text] [Related]
7. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes.
Kalsi V; Apostolidis A; Popat R; Gonzales G; Fowler CJ; Dasgupta P
Eur Urol; 2006 Mar; 49(3):528-35. PubMed ID: 16426735
[TBL] [Abstract][Full Text] [Related]
8. How long does the effect of botulinum toxin in neurogenic patients last? An analysis of the subset of "good responders".
Dominique I; Tremblais B; Charvier K; Nogueira MCS; Paparel P; Journel NM; Ruffion A
Low Urin Tract Symptoms; 2020 May; 12(2):155-161. PubMed ID: 31856406
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity.
Chen SF; Kuo HC
J Formos Med Assoc; 2015 Jul; 114(7):583-9. PubMed ID: 24262922
[TBL] [Abstract][Full Text] [Related]
10. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.
Popat R; Apostolidis A; Kalsi V; Gonzales G; Fowler CJ; Dasgupta P
J Urol; 2005 Sep; 174(3):984-9. PubMed ID: 16094019
[TBL] [Abstract][Full Text] [Related]
11. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
Chen G; Liao L
Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094
[TBL] [Abstract][Full Text] [Related]
12. Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.
Ghalayini IF; Al-Ghazo MA; Elnasser ZA
Int Urol Nephrol; 2009 Dec; 41(4):805-13. PubMed ID: 19184509
[TBL] [Abstract][Full Text] [Related]
13. Are 200 units of onabotulinumtoxin A sufficient for the suppression of neurogenic detrusor overactivity in individuals with established 300-unit botulinum toxin treatment? A retrospective cohort study.
Krebs J; Pannek J; Rademacher F; Wöllner J
World J Urol; 2021 Feb; 39(2):543-547. PubMed ID: 32322995
[TBL] [Abstract][Full Text] [Related]
14. Value of Urinary Brain-Derived Neurotrophic Factor Levels on the Assessment of Botulinum Toxin Type A Treatment for Neurogenic Detrusor Overactivity in Children with Myelodysplasia.
Sekerci CA; Tanidir Y; Toprak T; Basok BI; Isman F; Simsek F; Akbal C; Tarcan T
J Urol; 2019 Jan; 201(1):174-180. PubMed ID: 30577408
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
Conte A; Giannantoni A; Proietti S; Giovannozzi S; Fabbrini G; Rossi A; Porena M; Berardelli A
Eur J Neurol; 2012 May; 19(5):725-32. PubMed ID: 22212295
[TBL] [Abstract][Full Text] [Related]
17. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
18. The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia.
Top T; Sekerci CA; Isbilen-Basok B; Tanidir Y; Tinay I; Isman FK; Akbal C; Simsek F; Tarcan T
Neurourol Urodyn; 2017 Sep; 36(7):1896-1902. PubMed ID: 28090659
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
Pannek J; Göcking K; Bersch U
BJU Int; 2009 Nov; 104(9):1246-50. PubMed ID: 19426192
[TBL] [Abstract][Full Text] [Related]
20. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity.
Kim SW; Choi JH; Lee YS; Han SW; Im YJ
Urology; 2014 Dec; 84(6):1480-4. PubMed ID: 25432842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
